QuikFlo Health Shareholder Update

CALGARY, ALBERTA--(Marketwired - Jan. 4, 2016) - QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSX VENTURE:QF)(FRANKFURT:1QF) is pleased to announce our year end shareholder letter.

To our Shareholders,

For QuikFlo, 2015 was a seminal year. Early in the year, QuikFlo was only an idea, born and given life by our founding team's desire to improve stroke outcomes worldwide. As we close out 2015, QuikFlo is a public company with meaningful accomplishments behind it in every dimension critical to our success: fundraising, product development, recruiting, corporate governance, and honing our vision for the company.

I joined the company in mid-September, and in just the last three months, our team has:

• Closed our first financing round of $500,000
• Hired our first three full-time staff members
• Filed our first patent application
• Brought on Dr. Nils Forkert as our Head of Research
• Published groundbreaking research featured on the cover of the journal Stroke
• Been recognized for one of the top 5 publications of 2015 by the journal Radiology
• Submitted grant applications for potentially millions of dollars in non-dilutive funding
• Became actively traded on the TSX Venture Exchange under the symbol QF

Our high level of productivity results from a team that is extraordinarily talented, and driven by a compelling need to help the millions of people affected by stroke every year. Through the course of the coming year, we will continue to publish more thought-leading research, bolster our patent portfolio, add more exceptional people to our team, and convince more investors of the inevitability of our success. Moreover, we will continue realizing our product vision for FAST - Fast, Accurate Stroke Triage - to satisfy the market's need to improve stroke outcomes through better and faster decision-making.

Why build software to improve stroke triage? The answer is simple: short of a miracle drug, fixing the inefficient stroke triage process is the best way to improve stroke outcomes across the globe. Time is brain saved, and when triage and treatment decisions are delayed, patients suffer. QuikFlo codifies our founders' expertise into a software product that can guide physicians - anywhere in the world, and at any time of day - towards the right triage decision quickly. Patients are better served, hospitals run more efficiently and profitably, and the burden of stroke on society lessens.

We believe that a fundamentally important measure of our success is the shareholder value we create over the long-term. Stroke triage improvement represents an emerging market that will grow exponentially as the incidence of stroke, which is expected to double over the next 20 years, forces more hospitals to invest in solutions that produce better outcomes for patients and better economics for themselves. Because of our team and our vision for serving this market, QuikFlo is well-positioned to establish a leadership position as the potential of this market becomes reality. If we execute well, this is a position we can maintain for decades to come.

As always, my virtual door is open to you to hear your ideas, thoughts, and concerns. I look forward to corresponding with you, and communicating QuikFlo's progress to you in the coming year.

Yours,

Vinny Jindal

About QuikFlo

QuikFlo Health is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

Further Information

For further information relating to the Company or this release please visit www.sedar.com or www.quikflohealth.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Company's corporate strategy. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the suitability of the key members of ongoing management and the board of directors, the commercial opportunities available to the Company based on the technology acquired, and the ability of the Company to obtain sufficient funds to commercialize any product. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties is set forth in the circular.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.